Multivariable logistic regression models testing the association between HA-1 disparity and outcomes after hematopoietic cell transplantation
| End point . | HA-1 disparity . | Odds ratio (95% CI)* . | Adjusted P* . | |
|---|---|---|---|---|
| Absent (%) . | Present (%) . | |||
| Grades II to IV acute GVHD† | 244/494 (49) | 40/71 (56) | 1.5 (0.9-2.6) | .14 |
| Extensive chronic GVHD‡ | 193/419 (46) | 27/56 (48) | 1.0 (0.7-1.5) | .93 |
| Relapse1-153 | 144/496 (29) | 11/65 (17) | 0.6 (0.3-1.2) | .14 |
| Nonrelapse mortality1-155 | 151/529 (29) | 25/69 (36) | 1.3 (0.8-1.9) | .26 |
| Disease-free survival1-155 | 295/529 (56) | 26/69 (52) | 1.0 (0.7-1.4) | .92 |
| Mortality | 1.1 (0.7-1.5) | .77 | ||
| 1 year (%) | 35 | 40 | ||
| 5 years (%) | 49 | 50 | ||
| End point . | HA-1 disparity . | Odds ratio (95% CI)* . | Adjusted P* . | |
|---|---|---|---|---|
| Absent (%) . | Present (%) . | |||
| Grades II to IV acute GVHD† | 244/494 (49) | 40/71 (56) | 1.5 (0.9-2.6) | .14 |
| Extensive chronic GVHD‡ | 193/419 (46) | 27/56 (48) | 1.0 (0.7-1.5) | .93 |
| Relapse1-153 | 144/496 (29) | 11/65 (17) | 0.6 (0.3-1.2) | .14 |
| Nonrelapse mortality1-155 | 151/529 (29) | 25/69 (36) | 1.3 (0.8-1.9) | .26 |
| Disease-free survival1-155 | 295/529 (56) | 26/69 (52) | 1.0 (0.7-1.4) | .92 |
| Mortality | 1.1 (0.7-1.5) | .77 | ||
| 1 year (%) | 35 | 40 | ||
| 5 years (%) | 49 | 50 | ||
CI indicates confidence interval.
Odds ratios compare results for patients with HA-1 disparity against those for patients without HA-1 disparity. P values were adjusted by date of transplantation, age at transplantation, disease risk category, and use of total body irradiation as described previously.2
Excluding 40 patients without data for acute GVHD available at the time of analysis.
Excluding 130 patients who died or had recurrent malignancy within 80 days after the transplantation.
Excluding 37 patients with aplastic anemia and 7 patients with CML treated with interferon after molecular diagnostic tests showed bcr-abl rearrangement between 6 to 12 months after the transplantation.
Excluding 7 patients with CML treated with interferon as described above.